Homocysteine is a bystander for ST-segment elevation myocardial infarction: a case-control study

Table 3 Relationship between the severity of ST-segment elevation myocardial infarction (STEMI) and laboratory parameters

	Killip I	Killip II	Killip III	Killip IV	p value
Number, n	35	5	2	14
Age, years	60.0 ± 13.5	63.6 ± 13.5	57.5 ± 12.0	51.3 ± 10.6	0.141
Symptom to hospital, h	4.6 ± 5.1	1.2 ± 1.3	0.5 ± 0.7	5.6 ± 5.4	0.249
Aborted sudden death, n(%)	1(3)	0	0	6(43)	0.001*
VT/Vf, n(%)	1(3)	0	0	5(36)	0.007*
ECMO, n(%)	0	0	0	3(21)	0.023*
IABP, n(%)	0	0	0	9(64)	< 0.001*
Follow-up time, months	19.3 ± 2.1	18.0 ± 1.1	19.0 ± 1.8	16.9 ± 7.3	0.299
Mortality, n(%)	0	0	0	2(15)	0.082
White cell count, × 10⁹/L	11.44 ± 3.5	13.7 ± 1.9	13.7 ± 6.2	12.0 ± 4.9	0.577
White cell count, × 10⁹/L	11.7 ± 3.4		12.2 ± 4.9		0.704
Homocysteine, μmol/L	9.2 ± 5.3	12.9 ± 10.9	11.0 ± 3.7	8.0 ± 2.4	0.361
Homocysteine, μmol/L	9.7 ± 6.1		8.4 ± 2.6		0.256
C-reactive protein, mg/L	1.4 ± 2.3	1.4 ± 2.5	3.6 ± 3.9	3.3 ± 4.3	0.208
C-reactive protein, mg/L	1.4 ± 2.3		3.3 ± 4.1		0.032*
Low-density lipoprotein Cholesterol, mg/dL	116 ± 38	102 ± 30	127 ± 49	101 ± 41	0.574
Low-density lipoprotein Cholesterol, mg/dL	114 ± 37		104 ± 41		0.434
Peak creatine kinase (CK), IU/L	2100 ± 1391	3737 ± 3604	2595 ± 2773	3967 ± 2134	0.016*
Peak creatine kinase (CK), IU/L	2305 ± 1822		3796 ± 2163		0.023*
Time to peak CK, h	10.4 ± 4.6	9.8 ± 4.0	6.5 ± 5.0	8.6 ± 4.0	0.460
SYNTAX score	14.2 ± 7.6	19.0 ± 6.8	20.0 ± 7.1	20.46 ± 11.7	0.123
SYNTAX score	14.8 ± 7.6		20.4 ± 11.1		0.033*

ISSN: 1471-2261